Gout flares are associated with cardiovascular events. Treating gout to target serum urate levels prevents flares, but whether such treatment can also prevent cardiovascular events is unknown. An ...

Despite widespread awareness that gout is a chronic disease, significant misunderstanding remains about how it should be treated and how serious it can become, according to new research commissioned ...

Once gout has been diagnosed, the cause of the hyperuricemia should be identified. The two most common causes of hyperuricemia are decreased renal elimination of urate and excessive alcohol intake. A ...

Over the years, gout has grown in clinical complexity. We see many more cases with iatrogenic factors, multiple comorbidities, advanced age and treatment-refractory hyperuricemia and arthritis (Table ...

There are major gaps in quality of care in management of gout. Health care professionals should assess the serum urate level in patients at risk for gout and monitor serum urate regularly during urate ...

Gout, the most common form of inflammatory arthritis, often coexists with comorbidities that require integrated assessment and treatment. The burden of cardiovascular-kidney-metabolic (CKM) ...

When you think of arthritis, achy, warm, swollen joints probably come to mind. These are indeed some of the most common symptoms of arthritis. But did you know there are actually over 100 different ...

A groundbreaking new study, led by experts at the University of Nottingham, has found that medicines used to treat gout can also reduce the risk of heart attack and stroke in people with gout. The new ...

Each month, Clinical Advisor makes one new clinical feature available ahead of print. Don’t forget to take the poll. The results will be published in the next month’s issue. Each year there are 3.9 ...

Xanthine oxidase inhibitors, primarily allopurinol and febuxostat, are the mainstay of treatment. The goal of chronic gout management includes lowering serum urate levels to below 6 mg/dL. 5 Overall, ...

Worries that urate-lowering therapy (ULT) could speed renal failure in patients with gout and chronic kidney disease (CKD) are unfounded, data from Great Britain indicated. In a so-called "target ...